Neurotrophin-3-induced production of nerve growth factor is suppressed in Schwann cells exposed to high glucose: Involvement of the polyol pathway

Journal of Neurochemistry

Volumn 91, Issue 6, 2004, Pages 1430-1438

  Suzuki, Takeshi ^a   Sekido, Hiromi ^a   Kato, Noriaki ^a   Nakayama, Yukiharu ^a   Yabe Nishimura, Chihiro ^b  

^a SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Aldose reductase; Diabetic neuropathy; Nerve growth factor; Neurotrophin 3; Oxidative stress; Schwann cells

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; CILIARY NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ENZYME INHIBITOR; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; FIDARESTAT; FORSKOLIN; GLUCOSE; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; K 252A; K 252B; LEUKEMIA INHIBITORY FACTOR; NERVE GROWTH FACTOR; NEUROTROPHIN 3; PLATELET DERIVED GROWTH FACTOR; POLYOL; SCATTER FACTOR; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; UO 126; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; ENZYME INHIBITION; GLUCOSE METABOLISM; HYPESTHESIA; MALE; NERVE CELL CULTURE; NERVE REGENERATION; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; SCHWANN CELL;

ALDEHYDE REDUCTASE; ANIMALS; BINDING, COMPETITIVE; CELLS, CULTURED; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLUCOSE; GLUTATHIONE; MALE; NERVE GROWTH FACTOR; NEUROTROPHIN 3; NF-KAPPA B; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, TRKC; SCHWANN CELLS; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 10644277877     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02824.x     Document Type: Article

References (70)

1. Anton E. S., Weskamp G., Reichardt L. F. and Matthew W. D. (1994) Nerve growth factor and its low-affinity receptor promote Schwann cell migration. Proc. Natl Acad. Sci. USA 91, 2795-2799.
2. Bentley C. A. and Lee K. F. (2000) p75 is important for axon growth and schwann cell migration during development. J. Neurosci. 20, 7706-7715.
3. Boulton A. J., Levin S. and Comstock J. (1990) A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 33, 431-437.
4. Bravi M. C., Pietrangeli P., Laurenti O., Basili S., Cassone-Faldetta M., Ferri C. and De Mattia G. (1997) Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients. Metabolism 46, 1194-1198.
5. Bunge R. P. (1993) Expanding roles for the Schwärm cell: ensheathment, myelination, trophism and regeneration. Curr. Opin. Neurobiol. 3, 805-809.
6. Cai F., Tomlinson D. R. and Fernyhough P. (1998) Effect of sciatic nerve crush on local and target tissue production of neurotrophin-3 transcripts in rats. Neurosci. Lett. 252, 45-48.
7. Chakrabarti S., Sima A. A. F., Nakajima T., Yagihashi S. and Green D. A. (1987) Aldose reductase in the BB rat: isolation, immunological identification and localization in the retina and peripheral nerve. Diabetologia 30, 244-251.
8. Chandler C. E., Parsons L. M., Hosang M. and Shooter E. M. (1984) A monoclonal antibody modulates the interaction of nerve growth factor with PC12 cells. J. Biol. Chem. 259, 6882-6889.
9. Chen J. K., Yao L. L. and Jenq C. B. (1991) Mitogenic response of rat Schwann cells to fibroblast growth factors is potentiated by increased intracellular cyclic AMP levels. J. Neurosci. Res. 30, 321-327.
10. Colangelo A. M., Johnson P. F. and Mocchetti I. (1998) β-Adrenergic receptor-induced activation of nerve growth factor gene transcription in rat cerebral cortex involves CCAAT/enhancer-binding protein δ. Proc. Natl Acad. Sci. USA 95, 10 920-10 925.
11. Dowsing B. J., Morrison W. A., Nicola N. A., Starkey G. P., Bucci T. and Kilpatrick T. J. (1999) Leukemia inhibitory factor is an autocrine survival factor for Schwann cells. J. Neurochem. 73, 96-104.
12. Ehrhard P. B., Ganter U., Bauer J. and Otten U. (1993) Expression of functional trk protooncogene in human monocytes. Proc. Natl Acad. Sci. USA 90, 5423-5427.
13. Fu S. Y. and Gordon T. (1997) The cellular and molecular basis of peripheral nerve regeneration. Mol. Neurobiol. 14, 67-116.
14. Funakoshi H., Frisén J., Barbany G., Timmusk T., Zachrisson O., Verge V. M. K. and Persson H. (1993) Differential expression of mRNAs for neurotrophins and their receptors after axotomy of the sciatic nerve. J. Cell Biol. 123, 455-465.
15. Goss J. R., Coins W. F., Lacomis D., Mata M., Glorioso J. C. and Fink D. J. (2002) Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. Diabetes 51, 2227-2232.
16. Greene D. A., Lattimer S., Ulbrecht J. and Carroll P. (1985) Glucose-induced alterations in nerve metabolism: current perspective on the pathogenesis of diabetic neuropathy and future directions for research and therapy. Diabetes Care 8, 290-299.
17. Greene D. A., Arezzo J. C., Brown M. B. and the Zenarestat Study Group (1999) Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology 53, 580-591.
18. Haggiag S., Chebath J. and Revel M. (1999) Induction of myelin gene expression in Schwann cell cultures by an interleukin-6 receptor-interleukin-6 chimera. FEBS Lett. 457, 200-204.
19. Hellweg R. and Hartung H.-D. (1990) Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J. Neurosci. Res. 26, 258-267.
20. Heumann R., Lindholm D., Bandtlow C., Meyer M., Radeke M. J., Misko T. P., Shooter E. and Thoenen H. (1987) Differential regulation of mRNA encoding nerve growth factor and its receptor in rat sciatic nerve during development, degeneration, and regeneration: Role of macrophages. Proc. Natl Acad. Sci. USA 84, 8735-8739.
21. Horie H., Sakai I., Akahori Y. and Kadoya T. (1997) IL-1β enhances neurite regeneration from transected-nerve terminals of adult rat DRG. Neuroreport 8, 1955-1959.
22. Hotta N., Sakamoto N., Shigeta Y., Kikkawa R. and Goto Y. (1996) Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. J. Diabetes Complications 10, 168-172.
23. Hotta N., Toyota T., Matsuoka K. et al. (2001) Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 24, 1776-1782.
24. Judzewitsch R. G., Jaspan J. B., Polonsky K. S. et al. (1983) Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N. Engl. J. Med. 308, 119-125.
25. Kaplan D. R. and Miller F. D. (2000) Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 10, 381-391.
26. Kato N., Mizuno K., Matsubara A., Nakano K., Kurono M. and Yagihashi S. (1994) Effect of long-term treatment with a new aldose reductase inhibitor, (2S,45)-6-fluoro-2′,5′-dioxospiro-[chroman-4,4′-imidazolidine] -2-carboxamide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats. J. Diabetes Complications 8, 27-32.
27. Kennedy J. M. and Zochodne D. W. (2000) The regenerative deficit of peripheral nerves in experimental diabetes: its extent, timing and possible mechanismus. Brain 123, 2118-2129.
28. Kern T. S. and Engerman R. L. (1982) Immunohistochemical distribution of aldose reductase. Histochem. J. 14, 507-515.
29. Kinoshita J. H. (1974) Mechanisms initiating cataract formation, Proctor Lecture. Invest. Ophthamol. 13, 713-724.
30. Klein R., Nanduri V., Jing S. A., Lamballe F., Tapley P., Bryant S., Cordon-Cardo C., Jones K. R., Reichardt L. F. and Barbacid M. (1991) The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell 66, 395-403.
31. Korompilias A. V., Chen L. E., Seaber A. V. and Urbaniak J. R., (1999) Interleukin-1 beta promotes functional recovery of crushed peripheral nerve. J. Orthop. Res. 17, 714-719.
32. Krasnoselsky A., Massay M. J., DeFrances M. C., Michalopoulos G., Zarnegar R. and Ratner N. (1994) Hepatocyte growth factor is a mitogen for Schwann cells and is present in neurofibromas. J. Neurosci. 14, 7284-7290.
33. Krentz A. J., Honigsberger L., Ellis S. H., Hardman M. and Nattrass M. (1992) A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy. Diabet. Med. 9, 463-468.
34. Lamballe F., Klein R. and Barbacid M. (1991) TrkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell 66, 967-979.
35. Lee A. Y. W. and Chung S. S. M. (1999) Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J. 13, 23-30.
36. Lindholm D., Heumann R., Meyer M. and Thoenen H. (1987) Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve. Nature 330, 658-659.
37. Lindholm D., Heumann R., Hengerer B. and Thoenen H. (1988) Interleukin 1 increases stability and transcription of mRNA encoding nerve growth factor in cultured rat fibroblasts. J. Biol. Chem. 263, 16 348-16 351.
38. Ljungberg C., Novikov L., Kellerth J.-O., Ebendal T. and Wiberg M. (1999) The neurotrophins NGF and NT-3 reduce sensory neuronal loss in adult rat after peripheral nerve lesions. Neurosci. Lett. 262, 29-32.
39. Lobsiger C. S., Schweitzer B., Taylor V. and Suter U. (2000) Platelet-derived growth factor-BB supports the survival of cultured rat Schwann cell precursors in synergy with neurotrophin-3. Glia 30, 290-300.
40. Matsuoka I., Meyer M. and Thoenen H. (1991) Cell-type-specific regulation of nerve growth factor (NGF) synthesis in non-neuronal cells: comparison of Schwann cells with other cell types. J. Neurosci. 11, 3165-3177.
41. McArthur J. C., Yiannoutsos C., Simpson D. M. et al. (2000) A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. Neurology 54, 1080-1088.
42. Meier C., Parmantier E., Brennan A., Mirsky R. and Jessen K. R. (1999) Developing Schwann cells acquire the ability to survive without axons by establishing an autocrine circuit involving insulin-like growth factor, neurotrophin-3, and platelet-derived growth factor-BB. J. Neurosci. 19, 3847-3859.
43. Mîinea C., Kuruvilla R., Merrikh H. and Eichberg J. (2002) Altered arachidonic acid biosynthesis and antioxidant protection mechanisms in Schwann cells grown in elevated glucose. J. Neurochem. 81, 1253-1262.
44. Mizisin A. P., Li L., Perello M., Freshwater J. D., Kalichman M. W., Roux L. and Calcutt N. A. (1996) Polyol pathway and osmoregulation in JS1 Schwann cells grown in hyperglycemic and hyperosmotic conditions. Am. J. Physiol. 270, F90-F97.
45. Mizuno K., Kato N., Matsubara A., Nakano K. and Kurono M. (1992) Effects of a new aldose reductase inhibitor, (2S,45)-6-fluoro-2′,5′- dioxospiro[chroman-4,4′-imidazolidine]-2-carboxamide (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats. Metabolism 41, 1081-1086.
46. Nakamura J., Kasuya Y., Hamada Y., Nakashima E., Naruse K., Yasuda Y., Kato K. and Hotta N. (2001) Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity. Diabetologia 44, 480-487.
47. Obrosova I. G., Van Huysen C., Fathallah L., Cao X., Greene D. A. and Stevens M. J. (2002) An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism and antioxidative defense. FASEB J. 16, 123-125.
48. Obrosova I. G., Minchenko A. G., Vasupuram R., White L., Abatan O. I., Kumagai A. K., Frank R. N. and Stevens M. J. (2003) Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 52, 864-871.
49. Peulve P., Laquerriere A., Paresy M., Hemet J., Tadie M. (1994) Establishment of adult rat Schwann cell cultures: effect of b-FGF, alpha-MSH, NGF, PDGF, and TGF-beta on cell cycle. Exp. Cell Res. 214, 543-550.
50. Scarpini E., Conti G. C., Bussini S., Clerici R., Siglienti I., Piccio L., De Pol A., Baron P. L. and Scarlato G. (1999) Human schwann cell proliferation and IL-6 production following TNF-alpha stimulation in vitro. Ann. N. Y. Acad. Sci. 883, 520-522.
51. Schreck R., Rieber P. and Baeuerle P. A. (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-I. EMBO J. 10, 2247-2258.
52. Segal R. A. (2003) Selectivity in neurotrophin signaling: theme and variations. Annu. Rev. Neurosci. 26, 299-330.
53. Shuto T., Horie H., Hikawa N., Sango K., Tokashiki A., Murata H., Yamamoto I. and Ishikawa Y. (2001) IL-6 up-regulates CNTF mRNA expression and enhances neurite regeneration. Neuroreport. 12, 1081-1085.
54. Smith G. M., Rabinovsky E. D., McManaman J. L. and Shine H. D. (1993) Temporal and spatial expression of ciliary neurotrophic factor after peripheral nerve injury. Exp. Neurol. 121, 239-247.
55. Sondell M., Lundborg G. and Kanje M. (1999) Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J. Neurosci. 19, 5731-5740.
56. Song Z., Fu D. T. W., Chan Y.-S., Leung S., Chung S. S. M. and Chung S. K. (2003) Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress. Mol. Cell. Neurosci. 23, 638-647.
57. Sterne G. D., Brown R. A., Green C. J. and Terenghi G. (1997) Neurotrophin-3 delivered locally via fibronectin mats enhances peripheral nerve regeneration. Eur. J. Neurosci. 9, 1388-1396.
58. Susaki Y., Shimizu S., Katakura K., Watanabe N., Kawamoto K., Matsumoto M., Tsudzuki M., Furusaka T., Kitamura Y and Matsuda H. (1996) Functional properties of murine macrophages promoted by nerve growth factor. Blood 88, 4630-4637.
59. Suzuki T., Mizuno K., Yashima S., Watanabe K., Taniko K., Suzuki T. and Yabe-Nishimura C. (1999) Characterization of polyol pathway in Schwann cells isolated from adult rat sciatic nerves. J. Neurosci. Res. 57, 495-503.
60. Syroid D. E., Zorick T. S., Arbet-Engels C., Kilpatrick T. J., Eckhart W. and Lemke G. (1999) A role for insulin-like growth factor-I in the regulation of Schwann cell survival. J. Neurosci. 19, 2059-2068.
61. Terada M., Yasuda H., Kikkawa R. and Shigeta Y (1996) Tolrestat improves nerve regeneration after crush injury in streptozocin-induced diabetic rats. Metabolism 45, 1189-1195.
62. Unger J. W., Klitzsch T., Pera S. and Reiter R. (1998) Nerve growth factor (NGF) and diabetic neuropathy in the rat: morphological investigations of the sural nerve, dorsal root ganglion, and spinal cord. Exp. Neurol. 153, 23-34.
63. Vo P. A. and Tomlinson D. R. (1999) The regeneration of peripheral noradrenergic nerves after chemical sympathectomy in diabetic rats: effects of nerve growth factor. Exp. Neurol. 157, 127-134.
64. Watson P. A., Nesterova A., Burant C. F., Klemm D. J. and Reusch J. E.-B. (2001) Diabetes-related changes in cAMP response element-binding protein content enhance smooth muscle cell proliferation and migration. J. Biol. Chem. 276, 46 142-46 150.
65. Xu G. and Sima A. A. F. (2001) Altered immediate early gene expression in injured diabetic nerve: implications in regeneration. J. Neuropathol. Exp. Neurol. 60, 972-983.
66. Yabe-Nishimura C. (1998) Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol. Rev. 50, 21-33.
67. Yamamoto M., Sobue G., Li M., Arakawa Y., Mitsuma T. and Kimata K. (1993) Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and low-affinity nerve growth factor receptor (LNGFR) mRNA levels in cultured rat Schwann cells; differential time- and dose-dependent regulation by cAMP. Neurosci. Lett. 152, 37-40.
68. Yamauchi J., Chan J. R. and Shooter E. M. (2003) Neurotrophin 3 activation of TrkC induces Schwann cell migration through the c-Jun N-terminal kinase pathway. Proc. Natl Acad. Sci. USA 100, 14 421-14 426.
69. Yue D. K., Hanwell M. A., Satchell P. M. and Turtle J. R. (1982) The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats. Diabetes 31, 789-794.
70. Zhong H., Voll R. E. and Ghosh S. (1998) Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol. Cell 1, 661-671.